
Cellix Bio

The content contains privileged, confidential and copyright protected information. Please do not share with anyone with out prior permission from the concerned

PIPELINE OVERVIEW



■ Neurology
 ■ Pain
 ■ CV&MD
 ■ Oncology
 ■ Infectious Diseases

CLX-101	Levetiracetam	CLX-110	Clopidogrel, Prasugrel	CLX-103	Mesalamine	MSTM - 101	Metformin
CLX-102	Venlafaxine, Desvenlafaxine	CLX-112	Miglitol	CLX-118	Diclofenac	CLX-155	Capecitabine and FU analogs
CLX-104	Eslicarbazapine	CLX-113	EPA-Pantethine	CLX-119	Diazoxide	CLX-156	AmifostineAM, Pilocarpine
CLX-105	Valproic acid	CLX-114	Arhalofenate	CLX-121	Dextromethorphan	CLX-157	Sulindac, Eflornithine
CLX-106	MonoMethyl Fumarate	CLX-115	Acetazolamide	CLX-122	Milnacipran	CLX-159	Miconazole, Fluconazole, Intra-, Vorni-
CLX-107	L-DOPA, Carbidopa	CLX-116	Bupivacaine Conjugates	CLX-123	GABA Analogs : Pregabalin	CLX-160	NSAIDs: Naproxen, Meloxicam etc
CLX-108	Gabapentin	CLX-117	Bupivacaine Salts	CLX-124	Levo-Bupivacaine Salts	CLX-161	Local Anesthetics Salt Forms
				CLX-131	Ketoprofen	CLX-182	Ribavirin Novel Conju



DEVELOPMENTS



CODE	INDICATION	CHEMISTRY	NON-CLINICAL	PATENT
CLX-101	Epilepsy/Seizures			
CLX-102	Depression/MDD			
CLX-103	Ulcerative Colitis			
CLX-104	Epilepsy/Seizures			
CLX-105	Epilepsy/Seizures			
CLX-106	Multiple Sclerosis			
CLX-107	Parkinson's Disease			
CLX-108	Neuropathic Pain			
CLX-110	Atherothrombosis			
CLX-112	Diabetes			
CLX-113	Hypertriglyceridemia			
CLX-114	Gout			
CLX-115	Glaucoma			
CLX-116	Post-Operative Pain			
CLX-117	Post-Operative Pain/Oral Mucositis			
CLX-118	Osteoarthritis Pain			
CLX-119	Type 1 Diabetes			
CLX-121	Depression/Cough			
CLX-122	Fibromyalgia/MDD			
CLX-123	Neuropathic Pain			
CLX-124	Post-Operative Pain / Analgesia			
CLX-131	Ocular Pain			
CLX-155	Cancer			
MSTM-101	Diabetes			
CLX-159	Candidiasis			

COLLABORATIONS



Pipeline Code	Therapeutic Area	Non-Clinical	Clinical	Collaboration / Licensing	Regulatory
GASTROINTESTINAL:					
CLX-103	Ulcerative Colitis	→			IND Filing: 2017
CLX-181	Familial Adenomatous Polyposis	→			IND Filing: 2017
CLX-155	Colorectal Cancer / Gastric Cancer	→			IND Filing: 2018
NEUROLOGY:					
CLX-106	Multiple Sclerosis	→			IND Filing: 2017
CLX-107	Parkinson's Disease	→			IND Filing: 2018
CLX-104	Seizures / Epilepsy	→			IND Filing: 2017
ONCOLOGY:					
CLX-117	Oral Mucositis	→			IND Filing: 2017 / 2018
CLX-156	Xerostomia	→			IND Filing: 2018
CLX-105	Solid Tumour	→			NCE
CLX-155	Breast Cancer / Head and Neck Cancer	→			IND Filing: 2018
CLX-157	Gastrointestinal Polyps	→			TBD
METABOLIC DISEASES:					
MSTM-101	Diabetes	→			IND Filing: 2017
MSTM-102	NASH/NAFLD	→			IND Filing: 2017
CLX-114	Gout	→		MTA	IND Filing: 2019
INFLAMMATION/PAIN:					
CLX-118	Inflammation / Pain	→			IND Filing: 2017
ORAL DISEASES:					
CLX-158	Regional Anaesthesia	→			IND Filing: 2018
CLX-159	Oropharyngeal Candidiasis	→			IND Filing: 2018

CLX-117:

- Logic Bio: [Equity: 50.1% RVL / 49.9% Cellix
- RVL : Responsible for the non-clinical and clinical development of CLX-117
- SPARK grant of UCONN Health, USA and later CT/VC Funding

CLX-106:

- Development Collaboration with V ClinBio, USA
- Upfront: USD 1 Million Payment
- 25% of Profit Sharing with Cellix Bio
- I.P : Retained with Cellix Bio and will be assigned during commercialization stage

CLX-118/157:

- Research Collaboration with Texas A&M University
- CLX-157: NIH, USA Funding
- CLX-118: Data generated and Development Collaboration


CLX-159:

- Anti-Fungal : Candiasis and Drug Resistant Anti-Fungal Activity Screening
- New Jersey Medical School – Rutgers Collaboration
- MIC screening and Efficacy Studies

US – FDA : Pre-IND / IND Filing Schedule : 505(b)(2) Pathway



2017



CLX-103	Efficacy 30 day Study and PRD/CMC development – Completion by Jan / Feb 2017 Tentative Pre-IND meeting with the US FDA: June/July 2017	Tox. Studies June/Sep 2017 IND Filing Target Oct/Nov 2017	US/EU/Other National Countries Patent Grant
MSTM-101	Efficacy 30 day Study and PRD/CMC development – Completion by Feb 2017 Tentative Pre-IND meeting with the US FDA: June/July 2017	Tox. Studies July/Oct 2017 IND Filing Target Nov/Dec 2017	US/EU/Other National Countries Patent Grant
CLX-117	Spray Form, UCONN, USA and Clinical Study - IRB Completion by Feb/ Mar 2017 Tentative Pre-IND meeting with the US FDA: May/June 2017	Tox. Studies June/July 2017 IND Filing Target Sep/Oct 2017	US/EU/Other National Countries Patent Grant
CLX-104	Efficacy 15 day Study and PRD/CMC development – Completion by Feb / Mar 2017 Tentative Pre-IND meeting with the US FDA: July/August 2017	Tox. Studies July/Aug 2017 IND Filing Target Oct/Nov 2017	US/EU/Other National Countries Patent Grant

Contact:

**Cellix Bio Private Limited,
Plot No.1177 B, Road No.56, Jubilee Hills,
Hyderabad - 500033, India.**

www.cellixbio.com

email: kmahesh@cellixbio.com